Загрузка...
Receptor Tyrosine Kinase-Targeted Cancer Therapy
In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) acti...
Сохранить в:
| Опубликовано в: : | Int J Mol Sci |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6274851/ https://ncbi.nlm.nih.gov/pubmed/30404198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19113491 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|